ORTIF / Ortho Regenerative Technologies initiates patient enrollment following completion of first patient surgery in US phase I/II rotator cuff tear repair clinical trial

Ortho Regenerative Technologies Inc (CSE:ORTH) announced that it has changed its corporate name to ChitogenX Inc to better reflect the company's expan more_horizontal

Noble Capital has repeated an 'Outperform' rating and C$1.35 (US$1.05) price target again tagged Ortho Regenerative Technologies Inc (CSE:ORTH) foll more_horizontal

Ortho Regenerative Technologies Inc (CSE:ORTH) announced that it has begun the enrollment of patients after the first patient surgery was completed i more_horizontal

Ortho Regenerative Technologies Inc (CSE:ORTH) has reported its financial results and highlights for the first quarter ended April 30, 2022. Among the more_horizontal

Ortho Regenerative Technologies Inc (CSE:ORTH) is developing novel tissue repair therapies with the goal of dramatically increasing the success rates more_horizontal

Ortho Regenerative Technologies Inc (CSE:ORTH) announced that it has received a $500,000 grant to advance the development of its secondary technology more_horizontal

Ortho Regenerative Technologies (CSE:ORTH) Inc said the United States Patent and Trademark Office (USPTO) has issued a patent related to the company' more_horizontal

Ortho Regenerative Technologies (CSE:ORTH) Inc told investors it closed an oversubscribed non-brokered private placement of units for gross proceeds o more_horizontal